Publication Archive NOX-A12

The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.

Interim data on dual inhibition of post- radiogenic angio-vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma from the first expansion arm of the Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Schaub C, Zeyen T, Sperk E, Mueller W, Sperk E, Hambsch P, Oster C, Grau F, Paech D, Müller W, Pietsch T, Schmeel LC, Grauer O, Renovanz M, Tabatabai G, Kebir S, Bisdas S, Güresir E, Glas M, Seidel C, Hölzel M, Herrlinger U.
SNO 2023 November 18.
Poster Presentation

Potential predictive biomarker for response to radiotherapy and CXCL12-inhibition in glioblastoma in the phase I/II GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, Zeyen T, Schaub C, Mueller W, Sperk E, Schmeel LC, Sahm K, Kebir S, Hambsch P, Pietsch T, Bisdas S, Glas M, Seidel C, Herrlinger U, Hölzel M.
ASCO 2023 June 03.
Poster Presentation

Dual inhibition of post-radiogenic angio- vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma – Interim data from the first expansion arm of the German Phase 1/2 GLORIA trial.
Giordano FA, Layer JP, Leonardelli S, Friker LL, Schaub C, Turiello R, Sperk E, Mildenberger I, Grau F, Paech D, Pietsch T, Mueller W, Grauer O, Renovanz M, Tabatabai G, Kebir S, Glas M, Bisdas S, Hambsch P, Seidel C, Hölzel M, Herrlinger U.
SNO 2022 November 18.
Poster Presentation

Giordano FA, Layer JP, Leonardelli S, Friker LL, Seidel C, Schaub C, Turiello R, Sperk E, Grau F, Paech D, Link B, Mueller W, Tabatabai G, Sahm K, Kebir S, Pietsch T, Glas M, Bisdas S, Herrlinger U, Hölzel M.
Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMTunmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial.
ASCO 2022 June.
Poster Presentation

Giordano FA, Layer JP, Leonardelli S, Friker L, Seidel C, Zeyen T, Schaub C, Sperk E, Grau F, Paech D, Radbruch A, Sahm K, Kebir S, Hambsch P, Pietsch T, Glas M, Bisdas S, Hölzel M, Herrlinge U.
CXCL12 inhibition in MGMT unmethylated glioblastoma – Results of an early proof-of-concept assessment in the multicentric phase I/II GLORIA trial (NCT04121455).
SNO 2021 November.
Slide Presentation

Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungelius JU, Baumann M, Mangasarian A, Halama N.
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects.
J Immunother Cancer 2021, 9, e002505.
read article on bmj.com

Halama N, Williams A, Suarez-Carmona M, Schreiber J, Hohmann N, Prüfer U, Krauss J, Jäger D, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
Final Top-Line Data: CXCL12 inhibitor NOX-A12 and pembrolizumab in microsatellite-stable, metastatic colorectal or pancreatic cancer.
ESMO 2020 (09), Poster Presentation.
Poster

Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
Clinical outcome and safety in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab.
AACR 2019 (04), Poster Presentation.
Poster

Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
Correlation of clinical benefit with target neutralization and immune response in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab.
ESMO 2018 (11), Poster Presentation.
Poster

Halama N, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A.
Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.
CRI-CIMT-EATI-AACR 2018 (09), Poster Presentation.
Poster

Monzel C, Becker AS, Saffrich R, Wuchter P, Eckstein V, Ho AD, Tanaka M.
Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.
Sci Rep. 2018, 8(1), 1841.
read abstract on pubmed.gov

Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Oncotarget. 2017, 8(66), 109973-84.
read abstract on pubmed.gov

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M.
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib – dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Leukemia. 2017, 31, 997-1000.
read article on pubmed.gov

Deng L, Stafford JH, Liu SC, Chernikova SB, Merchant M, Recht L, Martin Brown J.
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Neoplasia. 2017, 19(1), 1-7.
read abstract on pubmed.gov

Zboralski D, Hoehlig K, Eulberg D, Froemming A, Vater A.
Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade.
Cancer Immunol Res. 2017.
read article on aacrjournals.org

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Br J Haematol. 2017, 179(1), 36.
read abstract on pubmed.gov

Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
Clin Immunol. 2016.
read abstract on pubmed.gov

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Kruschinski A, Dümmler T, Riecke K, Ghia P, Caligaris-Cappio F, Gobbi M.
Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia.
ASH 2014, San Francisco
Poster

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Zojer N, Riecke K, Kruschinski A, Dümmler T, Foa R, Greil R, Yakoub-Agha I, Engelhardt M.
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma.
ASH 2014, San Francisco
Poster

Zboralski D, Vater A, Kruschinski A.
Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated by Rituximab and Obinutuzumab.
ASH 2014, San Francisco
Poster

Roccaro et al.
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy.
Cell Reports. 2014, 9(1), 118-28.
read article on cell.com

Liu S-C, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, Merchant M, Zboralski D, Zöllner S, Kruschinski A, Klussmann S, Recht L, Brown JM.
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats.
Neuro-Oncology. 2014, 16(1), 21-28.
read article on oxfordjournals.org

Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F.
Hematopoietic stem and progenitor cell mobilization in mouse and man by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.
Clinical Pharmacology and Therapeutics. 2013, 94(1), 150-7.
read article on nature.com

Zboralski D, Hoellenriegel J, Maasch C, Kruschinski A, Burger JA
Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer NOX-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 318
read ASH abstract on hematologylibrary.org

Gobbi M, Caligaris-Cappio F, Montillo M, Vauléon S, Zöllner S, Dümmler T, Kruschinski A, Fliegert F
Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer NOX-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4593logylibrary
read ASH abstract on hematologylibrary.org

Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT.
Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2012, Vol. 186(9), 897-908.
view PubMed abstract on ncbi.nlm.nih.gov

Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ.
Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease.
Am J Pathol. 2011, Vol. 179(1), 116-24.
view PubMed abstract on ncbi.nlm.nih.gov

Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J.
Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.
Diabetologia 2009, Vol. 52(11), 2445-2454.
view PubMed abstract on ncbi.nlm.nih.gov